A confirmatory, multi-center, randomized Phase 3 study, KRYSTAL-12, evaluating adagrasib monotherapy versus docetaxel in patients with previously treated advanced KRAS G12C-mutant NSCLC, is ongoing (Table 2) (51). This evidence concerns the gene KRAS and non-small cell lung carcinoma.